Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / pleiotrophin

pleiotrophin

Basics

Aliases:
This biomarker is also known as:
  • HARP,
  • Heparin-binding neurite outgrowth-promoting factor 1,
  • HBGF8,
  • heparin affin regulatory protein,
  • osteoblast-specific factor 1,
  • PTN,
  • Heparin-binding growth factor 8,
  • heparin-binding growth-associated molecule,
  • HBGF-8,
  • Osteoblast-specific factor 1,
  • heparin-binding brain mitogen,
  • HBNF-1,
  • heparin-binding growth factor 8,
  • HBNF,
  • Heparin-binding growth-associated molecule,
  • HB-GAM,
  • NEGF1,
  • heparin-binding neurite outgrowth-promoting factor 1,
  • OSF-1,
  • pleiotrophin (heparin binding growth factor 8, neurite growth-promoting factor 1),
  • HBBM,
  • HBNF1,
  • heparin binding growth factor 8,
  • neurite growth-promoting factor 1,
  • Heparin-binding brain mitogen,

View in BioMuta

Description…

Pleiotrophin, or PTN, is a secreted growth factor found in osteoblasts and brain tissue. PTN induces neurite outgrowth and is mitogenic for fibroblasts, epithelial, and endothelial cells. It binds anaplastic lymphoma kinase (ALK) which induces MAPK pathway activation, an important step in the anti-apoptotic signaling of PTN and regulation of cell proliferation.

Attributes

QA State: Curated
Type: Protein
Short Name:
HGNC Name: PTN

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Lung

Attributes

Phase: Two
QA State: Curated

Overview

Pleiotrophin has been identified in serum and lung cancer tissue or cell culture as a candidate lung cancer biomarker. Pleiotrophin was also observed up-regulated in lung cancer in this study. Others studies have suggested that pleiotrophin may be an early indicator of lung cancer and might be of use in monitoring the efficacy of therapy.

Performance Comment

PTN, also known as pleiotrophin, is a member of a 12 protein panel that can discriminate NSCLC from controls with 91% sensitivity and 84% specificity in cross-validated training and 89% sensitivity and 83% specificity in a separate verification set, with similar performance for early and late stage NSCLC.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Announcement 10/07/2014

EDRN Patient Advocates will host an EDRN Advocacy Educational Webinar, Biomarkers for Prostate Cancer Detection and Monitoring, on Monday, January 12th, 2015, at 1 p.m. EDT / 10 a.m. PDT. Registration is not required for this. Please click for more information.
Announcement 09/14/2014

Thank you to everyone who helped make the 9th EDRN Scientific Workshop a success. We look forward to seeing everyone at the 28th EDRN Steering Committee Meeting from March 31-April 2, 2015, in Atlanta, GA.